Vad posterna betyder
- Publicering borttagen
- Publiceringen finns inte längre hos utgivaren. Posten ligger kvar här: en analys som tagits bort är fortfarande en analys som publicerats, och att låta den försvinna ur materialet vore att låta utgivaren redigera historiken i efterhand.
- Ny publicering
- En ny publicering har tillkommit hos utgivaren.
- Bevakning avslutad
- Utgivaren märker inte längre bolaget som aktivt bevakat.
- Bevisnivå stärkt
- Utgivaren redovisar nu mer om relationen än tidigare.
- Bevisnivå försvagad
- Utgivaren känns inte längre vid bolaget på den tidigare nivån. Det säger ingenting om att relationen upphört — en kundlista kan städas, och bolaget kan ha varit kund hela tiden. Det enda som ändrats är vad utgivaren själv skriver.
- Nytt bolag
- Bolaget har kommit in i urvalet efter att ha passerat tröskeln för upprepad bevakning.
- Utfallstyp ändrad
- Hur bolagets utfall räknas har ändrats — se bolagssidan för skälet och källan.
2026-10-27
137 händelser- Nytt bolag District Metals Analysguiden
- Ny publicering ByggPartner Gruppen Analysguiden VD-intervju Byggpartner Gruppen Q3-26
- Ny publicering Advenica Västra Hamnen Corporate Finance Advenica: Reaching a milestone with NATO
- Ny publicering Xvivo Perfusion Redeye Xvivo Perfusion (Q3 Review): Heart opportunity approaching
- Ny publicering Vitrolife Redeye Vitrolife (Q3 review): Technologies leads the way
- Ny publicering Vitec Software Group Redeye Vitec (Q3 Review): M&A engine set to accelerate
- Ny publicering Vertiseit Redeye Vertiseit (Q3 Review): Organic ARR Pick-Up and Swift Scala Integration Support the Case
- Ny publicering Truecaller Redeye Truecaller: Strong Q3 preliminary figures – India tax bill now has a number
- Ny publicering Stille Redeye Stille Q3: Improving profitability and strong cash flow generation
- Ny publicering SSH Communications Security Redeye SSH (Q3 Preview): A Soft Quarter Expected, Focus on Order Timing
- Ny publicering Senzime Redeye Senzime (Q3 Preview): A rebound needed to turn the tide
- Ny publicering Raysearch Redeye RaySearch (Q3 preview): The moment of truth
- Ny publicering q.beyond Redeye q.beyond: Cut 2026 guidance suggests soft Q4
- Ny publicering Plejd Redeye Plejd (Q3 Review): Norway Overloads the Circuit
- Ny publicering Physitrack Redeye Physitrack (Q3 Review): Back to growth: transition from add-on to platform
- Ny publicering OXE Marine Redeye OXE Marine (Q3 Review): Upbeat Q3 but overall demand remains soft
- Ny publicering Nanologica Redeye Nanologica: New CEO, updated strategy and SEK110.5m rights issue
- Ny publicering Modelon Redeye Modelon (Q3 Review): ARR turns – growth back on the agenda
- Ny publicering Litium Redeye Litium (Q3 Review): Profit Delivered, Free Shipping on Growth
- Ny publicering Litium Redeye Litium (Q3 Review): Profit Delivered, Free Shipping on Growth
- Ny publicering Lime Technologies Redeye Lime (Q3 Review): Steady delivery in a cautious market, AI adds upside
- Ny publicering I-tech Redeye I-Tech (Q3 Review): Navigating EU-BPR With a Strong Core
- Ny publicering Hexatronic Group Redeye Hexatronic (Q3 Review): Strong quarter all over, with Data Center in the lead
- Ny publicering Hacksaw Redeye Hacksaw (Q3 Preview): Slower growth momentum creates uncertainty
- Ny publicering Guldbrev Redeye Guldbrev (Q3 Review): Downgrades on Softer Volumes and Expansion costs, Yet Valuation Remains Attractive
- Ny publicering Genovis Redeye Weekly Edge Case – Genovis
- Ny publicering Gapwaves Redeye Gapwaves (Q3 Review): Volume beats, price lags
- Ny publicering Freemelt Redeye Freemelt: SEK 28m contract win
- Ny publicering ExpreS2ion Biotech Holding Redeye ExpreS2ion Biotech: Phase I fully enrolled, readout in Q1 2027
- Ny publicering Evolution Redeye Evolution (Q3 Review): Stable quarter, Brazil creates uncertainty
- Ny publicering Ependion Redeye Ependion (Q3 Review): Operating leverage kicking in
- Ny publicering Enea Redeye Enea (Q3 Review): Cheap, waiting for growth
- Ny publicering EG7 Redeye EG7 (Q3 Preview): Soft Aliens launch partly offset by solid portfolio
- Ny publicering Dynavox Group Redeye Dynavox Group (Q3 Review): Medicaid headwinds, margins intact
- Ny publicering BONESUPPORT Redeye BONESUPPORT (Q3 Review): A compelling setup for 2027
- Ny publicering Biovica International Redeye Biovica: Rights issue outcome announced
- Ny publicering Bioinvent International Redeye BioInvent: New RECIST Context to BI-1808 Data
- Ny publicering Bioinvent International Redeye BioInvent: Larger Cohort Confirms BI-1808 Efficacy
- Ny publicering Binero Group Redeye Binero Group (Q3 Review): Figures Support Current Forecast; Outlook Remains Healthy
- Ny publicering Avtech Sweden Redeye AVTECH (Q3 Review): First new airline pushed into 2027; value just above bear
- Ny publicering Annexin Pharmaceuticals Redeye Annexin (Q3 Review): Fully recruited study
- Ny publicering Alligator Bioscience Redeye Alligator Bioscience (Q3 Review): Partnering Mitazalimab to Fund HLX22
- Ny publicering Acarix Redeye Acarix: Regulatory approval for the CADScor System in Saudi Arabia
- Ny publicering Upsales Technology Kalqyl Upsales: VD-intervju med Johan Kallblad om Q3'26
- Ny publicering Upsales Technology Kalqyl Upsales: Rapportkommentar Q3'26
- Ny publicering Plejd Kalqyl Plejd: Rapportkommentar Q3’26
- Ny publicering Briox Kalqyl Briox: VD-intervju med Mikael Lindblom om Q3'26
- Ny publicering AIRA Kalqyl Aira: VD-intervju med Daniel Wikberg angående Q3'26
- Ny publicering AIRA Kalqyl Aira: Rapportkommentar Q3'26
- Ny publicering Acuvi Kalqyl Acuvi: VD-intervju med Nils Sjöholm om Q3'26
- Ny publicering Prebona Impala Nordic Prebona – Bevakningskommentar
- Ny publicering Wyld Networks Dagens Börs TEKNISK ANALYS: Wyld Networks – drone chip
- Ny publicering White Pearl Technology Group Dagens Börs TEKNISK ANALYS: WPTG – intäkterna på ATH!
- Ny publicering Titania Holding Dagens Börs TEKNISK ANALYS: Titania, substansvärde 26kr
- Ny publicering mResell Holding Dagens Börs TEKNISK ANALYS: mResell
- Ny publicering Candles Scandinavia Dagens Börs TEKNISK ANALYS: Candles Scandinavia
- Ny publicering Biofrigas Dagens Börs Erik Fromell VD Biofrigas – Order i sikte
- Ny publicering Vertiseit Carnegie/Penser uppdragsanalys Vertiseit: Organic growth acceleration, margin expansion – Q3 review
- Ny publicering Vertiseit Carnegie/Penser uppdragsanalys Vertiseit: Accelerating organic ARR growth – Q3 initial
- Ny publicering Terranor Group Carnegie/Penser uppdragsanalys Terranor: Focus on the margin – Q3 preview
- Ny publicering Svedbergs Group Carnegie/Penser uppdragsanalys Svedbergs Group: We expect a margin recovery in 2027 – Q3 review
- Ny publicering Spago Nanomedical Carnegie/Penser uppdragsanalys Spago Nanomedical: Move to go private
- Ny publicering Solar Foods Carnegie/Penser uppdragsanalys Solar Foods: Godert Zijlstra to leave Solar Foods at year-end 2026
- Ny publicering Scanfil Carnegie/Penser uppdragsanalys Scanfil: Strong quarter and improved visibility – Q3 review
- Ny publicering Scanfil Carnegie/Penser uppdragsanalys Scanfil: 26% adj. EBITA growth Y/Y – Q3 initial comment
- Ny publicering Qualisys Carnegie/Penser uppdragsanalys Qualisys: Delayed orders weigh on results – Q3 update
- Ny publicering Qualisys Carnegie/Penser uppdragsanalys Qualisys: Building towards a stronger H2 – Q3 preview
- Ny publicering Pricer Carnegie/Penser uppdragsanalys Pricer: Strong margins maintained – Q3 review
- Ny publicering Pricer Carnegie/Penser uppdragsanalys Pricer: Impressive gross margin expansion and EBIT – Q3 initial
- Ny publicering Pricer Carnegie/Penser uppdragsanalys Bactiguard: Licence engine gaining momentum – Q3 review
- Ny publicering PowerCell Sweden Carnegie/Penser uppdragsanalys PowerCell: Timing effects largely explain the weakness – Q3 initial
- Ny publicering PowerCell Sweden Carnegie/Penser uppdragsanalys PowerCell: Preparing for a wide range of outcomes in 2027 – Q3 review
- Ny publicering Paxman Carnegie/Penser uppdragsanalys Paxman: IBBM momentum versus opex – Q3 preview
- Ny publicering Ortoma Carnegie/Penser uppdragsanalys Ortoma: Secures breakthrough commercial order from partner
- Ny publicering Net Insight Carnegie/Penser uppdragsanalys Net Insight: Signs of increased market activity – Q3 preview
- Ny publicering MilDef Group Carnegie/Penser uppdragsanalys MilDef Group: Stronger backlog supports 2027 outlook – Q3 review
- Ny publicering MilDef Group Carnegie/Penser uppdragsanalys MilDef Group: Backlog visibility supports 2027 outlook – Q3 initial comment
- Ny publicering Micro Systemation Carnegie/Penser uppdragsanalys Micro Systemation: Strong momentum, multiple growth drivers – Q3 review
- Ny publicering Micro Systemation Carnegie/Penser uppdragsanalys Micro Systemation: Customer breach – MSAB technology intact
- Ny publicering Micro Systemation Carnegie/Penser uppdragsanalys Micro Systemation: A record quarter – Q3 initial comment
- Ny publicering Lindex Group Carnegie/Penser uppdragsanalys Lindex Group: Strong performance across the board – Q3 review
- Ny publicering Lindex Group Carnegie/Penser uppdragsanalys Lindex Group: Many contributors to strong group margins – Q3 initial
- Ny publicering Kebni Carnegie/Penser uppdragsanalys Kebni: Ready to scale, but orders must follow – Q3 initial comment
- Ny publicering Kebni Carnegie/Penser uppdragsanalys Kebni - Q3 (26) - Rapportintervju
- Ny publicering Kebni Carnegie/Penser uppdragsanalys Kebni: Pipeline conversion remains the key catalyst – Q3 review
- Ny publicering Idun Industrier Carnegie/Penser uppdragsanalys Idun Industrier: Earnings beat driven by Service & Maintenance – Q3 initial
- Ny publicering Idun Industrier Carnegie/Penser uppdragsanalys Idun Industrier: A strong comeback after the weaker Q2 – Q3 review
- Ny publicering Iconovo Carnegie/Penser uppdragsanalys Iconovo: Management upbeat on near-term deal – Q3 review
- Ny publicering HANZA Carnegie/Penser uppdragsanalys HANZA: BMK margin recovery continues – Q3 initial comment
- Ny publicering HAKI Safety Carnegie/Penser uppdragsanalys HAKI Safety: Organic weakness slows recovery – Q3 initial take
- Ny publicering HAKI Safety Carnegie/Penser uppdragsanalys HAKI Safety: Order delays cloud recovery; FV lowered – Q3 review
- Ny publicering Ependion Carnegie/Penser uppdragsanalys Ependion: Energy end-market likely to remain strong – Q3 review
- Ny publicering Ependion Carnegie/Penser uppdragsanalys Ependion – demand remains strong
- Ny publicering Ependion Carnegie/Penser uppdragsanalys Ependion: All-time high EBITA – Q3 initial
- Ny publicering Elanders Carnegie/Penser uppdragsanalys Elanders: Signs of recovery in fashion – Q3 review
- Ny publicering Elanders Carnegie/Penser uppdragsanalys Elanders: Sequentially stable demand – Q3 preview
- Ny publicering Elanders Carnegie/Penser uppdragsanalys Elanders: 6% Y/Y organic growth – Q3 initial
- Ny publicering CDON Carnegie/Penser uppdragsanalys CDON: Strong growth fending off toll uncertainty – Q3 initial
- Ny publicering CDON Carnegie/Penser uppdragsanalys CDON: Fyndiq surprises amid uncertainty – Q3 review
- Ny publicering Calviks Carnegie/Penser uppdragsanalys Calviks: Acquisitions aplenty, financing secured – Q3 preview
- Ny publicering Calviks Carnegie/Penser uppdragsanalys Calviks - Acquisitions aplenty, financing secured
- Ny publicering CAG Group Carnegie/Penser uppdragsanalys CAG - Q3 (26) - Rapportintervju
- Ny publicering CAG Group Carnegie/Penser uppdragsanalys CAG Group: Higher utilisation drives organic growth – Q3 initial comment
- Ny publicering CAG Group Carnegie/Penser uppdragsanalys CAG Group: Gradual recovery, resilient fundamentals – Q3 review
- Ny publicering Bonava Carnegie/Penser uppdragsanalys Bonava: German weakness delays recovery – Q3 initial take
- Ny publicering Bonava Carnegie/Penser uppdragsanalys Bonava: German slowdown delays recovery – Q3 review
- Ny publicering Bonava Carnegie/Penser uppdragsanalys Analyspodden - Avsnitt 387 - Bonava om bostadsmarknaden och vägen framåt
- Ny publicering Bokusgruppen Carnegie/Penser uppdragsanalys Bokusgruppen: Strong growth from acquisition – Q3 review
- Ny publicering Bokusgruppen Carnegie/Penser uppdragsanalys Bokusgruppen - Q3 (26) - Rapportintervju
- Ny publicering Bokusgruppen Carnegie/Penser uppdragsanalys Bokusgruppen: Acquisition support, some online uncertainty – Q3 preview
- Ny publicering Björn Borg Carnegie/Penser uppdragsanalys Björn Borg: Back to growth trajectory – Q3 initial
- Ny publicering Björn Borg Carnegie/Penser uppdragsanalys Björn Borg: Back to growth, margin expansion continues – Q3 review
- Ny publicering Besqab Carnegie/Penser uppdragsanalys Besqab: Margin strength supports recovery – Q3 initial take
- Ny publicering Besqab Carnegie/Penser uppdragsanalys Besqab: Margin strength brings targets closer – Q3 review
- Ny publicering Bergman & Beving Carnegie/Penser uppdragsanalys Bergman & Beving - Gröna skott
- Ny publicering Bergman & Beving Carnegie/Penser uppdragsanalys Bergman & Beving: Green shoots – Q2 review
- Ny publicering Bergman & Beving Carnegie/Penser uppdragsanalys Bergman & Beving: Continued EBITA growth – Q2 initial
- Ny publicering Bactiguard Holding Carnegie/Penser uppdragsanalys Bactiguard: Strong BD and stronger EBITDA – Q3 initial
- Ny publicering ALM Equity Carnegie/Penser uppdragsanalys ALM Equity: Starts accelerating; cash flow lagging – Q3 initial take
- Ny publicering ALM Equity Carnegie/Penser uppdragsanalys ALM Equity: Starting to accelerate, cash flow lags – Q3 review
- Ny publicering Zinzino Carlsquare Equity Research Analys Zinzino kv3 2026: Preview - Högre lönsamhet trots en viss tillväxtavmattning
- Ny publicering CDON Carlsquare Equity Research Equity research CDON Q3 2026: Strong GMV momentum and Fyndiq relief
- Ny publicering CDON Carlsquare Equity Research Equity research CDON Q3 2026: First impression - Better growth than expected
- Ny publicering ALM Equity Carlsquare Equity Research Analys ALM Equity, kv3 2026: Vinstlyft dröjer trots högre byggaktivitet
- Ny publicering ALM Equity Carlsquare Equity Research Analys ALM Equity, kv3 2026: Resultat som väntat trots låga intäkter
- Ny publicering Synexo Group Analyst Group Kommentar på Synexos avsiktsförklaring avseende ett andra förvärv inom hosting
- Ny publicering poLight Analyst Group Preview Comment on poLight’s Q3-26 Interim Report
- Ny publicering Mahvie Minerals Analyst Group Kommentar på Mahvie Minerals borresultat från Åkerberg
- Ny publicering Lumito Analyst Group Kommentar på utfallet av Lumitos pilotprojekt med Navinci Diagnostics
- Ny publicering Lumito Analyst Group Kommentar på Lumitos partnerskap med CRO-bolaget Aurevia
- Ny publicering EMB Mission Bound Analyst Group Kommentar på EMB Mission Bounds avtal om förvärv av MegaBet Plus
- Ny publicering Prisma Properties Analysguiden Prisma Properties: Kraftig resultatökning i tredje kvartalet
- Ny publicering Fastpartner Analysguiden Fastpartner: Fastpartner ser positiva sentiment i marknaden
- Ny publicering Eastnine Analysguiden Första intryck Eastnine: Förvärvet av The Bridge har slutförts
- Ny publicering Eastnine Analysguiden Eastnine: Warszawa är numera Eastnines största marknad
- Ny publicering ByggPartner Gruppen Analysguiden Byggpartner Gruppen: Oförtjänt rabattvärderad
- Ny publicering Beijer Alma Analysguiden Beijer Alma: Ökar marginalerna och laddar för nya förvärv
2026-10-19
11 händelser- Ny publicering q.beyond Redeye q.beyond: Solid momentum in Q3 new sales
- Ny publicering Invisio Redeye Invisio (Q3 Preview): Order intake in focus
- Ny publicering Carasent Redeye Carasent (Q3 Review): Infosolutions and Medsum taking the lead
- Ny publicering Plejd Kalqyl Plejd: VD-intervju med Babak Esfahani angående Q3'26
- Ny publicering Seamless Distribution Systems Impala Nordic Coverage comment – Seamless Distribution Systems
- Ny publicering Biofrigas Dagens Börs Erik Fromell, VD Biofrigas – uppskalningen
- Ny publicering PowerCell Sweden Carnegie/Penser uppdragsanalys PowerCell: Recovery yet to be seen – Q3 preview
- Ny publicering GiG Software Carnegie/Penser uppdragsanalys GiG Software: 888Africa not yet visible in the numbers – Q3 preview
- Ny publicering CAG Group Carnegie/Penser uppdragsanalys CAG Group: Market stabilisation supports the 2027 outlook – Q3 preview
- Ny publicering Bergman & Beving Carnegie/Penser uppdragsanalys Bergman & Beving: Expecting deal activity to pick up in fiscal H2 – Q2 preview
- Ny publicering eEducation Albert Carnegie/Penser uppdragsanalys eEducation Albert: Progress towards 2026 financial targets – Q3 preview
2026-10-16
53 händelser- Ny publicering aXichem Västra Hamnen Corporate Finance aXichem: aXivite-order i ny distributionskanal
- Ny publicering Xvivo Perfusion Redeye Xvivo Perfusion (Q3 preview): Heart opportunity approaches
- Ny publicering Xbrane Biopharma Redeye Xbrane Biopharma: Xdivane pivotal study fully recruited
- Ny publicering Vitrolife Redeye Vitrolife (Q3 preview): Earnings on the rise, FX adds support
- Ny publicering Stille Redeye Weekly Edge Case – Stille
- Ny publicering Siljansvik Redeye Siljansvik: Consolidating ownership ahead of next investment cycle
- Ny publicering SciBase Holding Redeye SciBase: First private payer coverage in the US
- Ny publicering Plejd Redeye Plejd (Q3 2026 Preview): LPN-01 ramps, but tough comps in Sweden
- Ny publicering Oncopeptides Redeye Oncopeptides: SEK100m Directed Issue Funds Glioblastoma
- Ny publicering Oncopeptides Redeye Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier
- Ny publicering KD Ventures Redeye KDventures: Safety Pause at Modus Delays Readout
- Ny publicering InCoax Networks Redeye InCoax: Deeply discounted rights issue secures funding
- Ny publicering I-tech Redeye I-Tech: Signs Aquaculture license agreement
- Ny publicering Hacksaw Redeye Hacksaw: Q3-results below expectations
- Ny publicering Hacksaw Redeye Hacksaw: Broadens product portfolio with prediction markets offer
- Ny publicering Freja eID Group Redeye Freja eID (Preliminary Q3): ARR growth roughly as expected
- Ny publicering Elicera Therapeutics Redeye Elicera: Strong finish to CARMA Phase I
- Ny publicering Avtech Sweden Redeye AVTECH: Key figures show a softer landing than feared
- Ny publicering Avensia Redeye Avensia: Slightly upbeat sales numbers for September and Q3 fuelled by strong growth in IM
- Ny publicering Ascelia Pharma Redeye Ascelia: Our comment on the FDA minutes
- Ny publicering JonDeTech Sensors Kalqyl JonDeTech Sensors: Rapportkommentar Q3'26
- Ny publicering Xoma Dagens Börs TEKNISK ANALYS: XOMA (+20,66%) ny framgång
- Ny publicering Peptonic Medical Dagens Börs TEKNISK ANALYS: Peptonic Medical ökar i USA
- Ny publicering MySafety Group Dagens Börs TEKNISK ANALYS: MySafety 1,35 kr/utdelning
- Ny publicering Vivesto Carnegie/Penser uppdragsanalys Vivesto: Key congress exposure for Paccal Vet data
- Ny publicering Vertiseit Carnegie/Penser uppdragsanalys Vertiseit: Support for ARR organic growth acceleration – Q3 preview
- Ny publicering Svedbergs Group Carnegie/Penser uppdragsanalys Svedbergs Group: Looking for the margin to recover in 2027e – Q3 preview
- Ny publicering Relais Group Carnegie/Penser uppdragsanalys Relais Group: We expect flattish earnings – Q3 preview
- Ny publicering Pricer Carnegie/Penser uppdragsanalys Pricer: Deal secured with Orange in France
- Ny publicering Pierce Group Carnegie/Penser uppdragsanalys Pierce: Steady through a bumpy patch – Q3 preview
- Ny publicering OssDsign Carnegie/Penser uppdragsanalys OssDsign: Q3 too early for the turnaround – Q3 preview
- Ny publicering MilDef Group Carnegie/Penser uppdragsanalys MilDef Group: Record order intake and strong end to 2026e – Q3 preview
- Ny publicering Micro Systemation Carnegie/Penser uppdragsanalys Micro Systemation: Q3 significantly better than expected – Q3 preview
- Ny publicering Lindex Group Carnegie/Penser uppdragsanalys Lindex Group: Support for cash flow growth in H2e – Q3 preview
- Ny publicering Kebni Carnegie/Penser uppdragsanalys Kebni: Focus shifts to 2027 – Q3 preview
- Ny publicering ITAB Group Carnegie/Penser uppdragsanalys ITAB Group: Profit margin and execution focus – Q3 preview
- Ny publicering Ependion Carnegie/Penser uppdragsanalys Ependion: Focusing on demand in trains and energy – Q3 preview
- Ny publicering Eolus Vind Carnegie/Penser uppdragsanalys Analyspodden - Avsnitt 385 - Konsten att utveckla framtidens förnybara energi med Eolus
- Ny publicering Elicera Therapeutics Carnegie/Penser uppdragsanalys Elicera Therapeutics: Phase I part of the CARMA trial now completed
- Ny publicering Elicera Therapeutics Carnegie/Penser uppdragsanalys Elicera Therapeutics - Johan Liwing om CARMA-resultaten och vägen mot Fas IIa
- Ny publicering Carasent Carnegie/Penser uppdragsanalys Carasent: Strong Q3 should validate the margin story – initial comment
- Ny publicering Carasent Carnegie/Penser uppdragsanalys Carasent: Q3 a hint of the profitability potential– Q3 review
- Ny publicering Carasent Carnegie/Penser uppdragsanalys Carasent - Q3 (26) - Rapportintervju
- Ny publicering Ascelia Pharma Carnegie/Penser uppdragsanalys Ascelia Pharma: FDA requests additional clinical evidence
- Ny publicering ALM Equity Carlsquare Equity Research Analys ALM Equity, kv3 2026: Flera byggstarter under kvartalet
- Ny publicering Zenith Energy Analyst Group Comment on Reveille’s Appointment of Mike Pompeo as Proposed Chairman
- Ny publicering Synexo Group Analyst Group Kommentar på Synexos septemberuppdatering
- Ny publicering Modus Therapeutics Analyst Group Kommentar på att Modus Therapeutics pausar rekryteringen i fas IIa-studien inom CKD med anemi
- Ny publicering Luxbright Analyst Group Kommentar på Luxbrights ytterligare order från Fisica om ca 1 MSEK
- Ny publicering Luxbright Analyst Group Kommentar på Luxbrights ordrar från Fisica om totalt ca 3,4 MSEK
- Ny publicering AcuCort Analyst Group AcuCort bjuder in till kapitalmarknadsdag den 13 oktober
- Ny publicering Coor Service Management Holding Analysguiden Inför rapporten Coor: En brytpunkt närmar sig
- Ny publicering Beijer Alma Analysguiden Beijer Alma: Preview Q3 2026
2026-10-09
21 händelser- Ny publicering Waystream Group Redeye Waystream (Q3 Review): Strong growth with multiple growth drivers
- Ny publicering Vitec Software Group Redeye Weekly Edge Case – Vitec Software Group
- Ny publicering Stille Redeye Stille (Q3 preview): Sustained growth with margins holding up
- Ny publicering Sleep Cycle Redeye Sleep Cycle: Reverse merger with Audiowell, second exit at SEK24.50
- Ny publicering PowerCell Sweden Carnegie/Penser uppdragsanalys PowerCell: Follow-up order for two additional bulk carriers
- Ny publicering HANZA Carnegie/Penser uppdragsanalys HANZA: Organic growth still in focus – Q3 preview
- Ny publicering Faron Pharmaceuticals Carnegie/Penser uppdragsanalys Faron Pharmaceuticals: R&D Day takeaways
- Ny publicering Arion Bank Carnegie/Penser uppdragsanalys Arion Bank: Minor model adjustments
- Ny publicering OncoZenge Redeye OncoZenge: SEK3.3m directed issue to specialist investors
- Ny publicering INQ Group Redeye INQ Group: Convertible conversion strengthens the balance sheet and shows owner conviction
- Ny publicering EG7 Redeye EG7: Fireshine expands portfolio with survival-crafting game Necesse
- Ny publicering BONESUPPORT Redeye BONESUPPORT (Q3 preview): Multiple drivers for a re-rating
- Ny publicering Alzinova Redeye Alzinova: Rights issue subscribed to 86.2%
- Ny publicering Xoma Dagens Börs TEKNISK ANALYS: XOMA visar teknisk styrka!
- Ny publicering Alzinova Dagens Börs TEKNISK ANALYS: Alzinova – stark emission!
- Ny publicering Waystream Group Carnegie/Penser uppdragsanalys Waystream: In the beginning of the replacement cycle – Q3 review
- Ny publicering Pricer Carnegie/Penser uppdragsanalys Pricer: Gross margins and savings to support profits – Q3 preview
- Ny publicering Mentice Carnegie/Penser uppdragsanalys Mentice: May be on track for five in a row – Q3 preview
- Ny publicering Arion Bank Carnegie/Penser uppdragsanalys Arion Bank: Higher bank tax overshadows operational gains – Q3 preview
- Ny publicering Alzinova Carnegie/Penser uppdragsanalys Alzinova: Rights issue completed
- Ny publicering CDON Carlsquare Equity Research Equity research CDON: Preview Q3 2026 - Fyndiq in focus
2026-10-07
30 händelser- Bevisnivå försvagad Absolicon Kalqyl Trolig kund, ej bekräftad → Upprepad bevakning
- Bevisnivå stärkt Wyld Networks Dagens Börs Märkt som sponsrad → Angiven som kund
- Ny publicering Waystream Group Redeye Waystream (Q3 Initial take): Strong growth with margins in line
- Ny publicering Vitec Software Group Redeye Vitec (Q3 preview): Solid seasonally strong quarter expected
- Ny publicering Truecaller Redeye Truecaller Q3 Preview: Continued sequential improvment
- Ny publicering Sleep Cycle Redeye Sleep Cycle (Q3 Preview): Top line turns, one-offs weigh
- Ny publicering q.beyond Redeye q.beyond: Value-creating buybacks completed
- Ny publicering Lime Technologies Redeye Lime (Q3 Preview): Lime Go turns AI-native, minor cost-mix trim to estimates
- Ny publicering InCoax Networks Redeye InCoax: Nokia shift leaves a larger funding gap
- Ny publicering FluoGuide Redeye FluoGuide: First patient enrolled in US Phase II registration-supporting trial
- Ny publicering FluoGuide Redeye FluoGuide: Collaboration with Leica Microsystems expands microscope coverage
- Ny publicering Enea Redeye Enea (Q3 2026 Preview): Back to growth
- Ny publicering Cheffelo Redeye Cheffelo: Comment on Q3 trading update
- Ny publicering Alligator Bioscience Redeye Alligator Bioscience: CFO Johan Giléus to Take Over as CEO
- Ny publicering Waystream Group Carnegie/Penser uppdragsanalys Waystream: Increased production at the end of the quarter – Q3 initial
- Ny publicering Waystream Group Carnegie/Penser uppdragsanalys Waystream – I början av utbytescykeln
- Ny publicering Scanfil Carnegie/Penser uppdragsanalys Scanfil: We look for 23% Y/Y adj. EBITA growth – Q3 preview
- Ny publicering Orexo Carnegie/Penser uppdragsanalys Orexo: Withdrawing fair value range
- Ny publicering Orexo Carnegie/Penser uppdragsanalys Orexo - Proposed capital raise supports next phase of development
- Ny publicering Mentice Carnegie/Penser uppdragsanalys Analyspodden - Avsnitt 384 - Mentice – från transformation till tillväxt och marginallyft
- Ny publicering HAKI Safety Carnegie/Penser uppdragsanalys HAKI Safety: Growth continues; Combisafe in focus – Q3 preview
- Ny publicering FluoGuide Carnegie/Penser uppdragsanalys FluoGuide: First US HGG patient enrolled – important clinical milestone
- Ny publicering FluoGuide Carnegie/Penser uppdragsanalys FluoGuide: Adds Leica as fifth medtech partner
- Ny publicering CDON Carnegie/Penser uppdragsanalys CDON: Eyes on tolls – Q3 preview
- Ny publicering BTS Group Carnegie/Penser uppdragsanalys BTS Group: H2 looking like a harvest period – Q3 preview
- Ny publicering Björn Borg Carnegie/Penser uppdragsanalys Björn Borg: Growth in focus after soft H1 expansion – Q3 preview
- Ny publicering Besqab Carnegie/Penser uppdragsanalys Besqab: Volume ramp remains on track – Q3 preview
- Ny publicering Lumito Analyst Group Kommentar på Lumitos investerarbrev och måluppföljning
- Ny publicering AcuCort Analyst Group Kommentar på AcuCorts företrädesemission om ca 70,3 MSEK
- Ny publicering Byggmästare Anders J Ahlström Holding Analysguiden Kommentar Byggmästare Anders J Ahlström: Fabriksbesök DPP
2026-10-03
9 händelser- Ny publicering Transtema Redeye Transtema (Q3 Preview): Small revisions
- Ny publicering Sprint Bioscience Redeye Sprint Bioscience: Vinnova funding for fragment screening project
- Ny publicering Physitrack Redeye Physitrack (Q3 Preview): Steady Growth, EMR in Focus
- Ny publicering Addnode Group Redeye Addnode (Q3 Preview): No drama expected
- Ny publicering AcouSort Redeye AcouSort: OEM and marketing agreements with Calyrex and Intelmetis, plus SEK15m convertible financing
- Ny publicering W5 Solutions Carnegie/Penser uppdragsanalys W5 Solutions: Financial position strengthened – withdrawing fair value
- Ny publicering Medivir Carnegie/Penser uppdragsanalys Medivir: A broader pipeline, stronger equity story – reinitiating coverage
- Ny publicering Nosa Plugs Analyst Group Comment on Nosa Plugs’ Distribution Agreement With Galls in the US
- Publicering borttagen Svenska Aerogel Carlsquare Equity Research Equity Research Svenska Aerogel, Q2 2024: Low revenues, but important orders in place
2026-10-02
14 händelser- Ny publicering W5 Solutions Redeye W5 Solutions: Raising SEK165m through directed share issue
- Ny publicering SciBase Holding Redeye SciBase: Rights issue outcome
- Ny publicering Momentum Group Redeye Weekly Edge Case – Momentum Group
- Ny publicering Hexatronic Group Redeye Hexatronic (Q3 Preview): Fiber margin recovery, Harsh trimmed
- Ny publicering Gentoo Media Redeye Gentoo Media: Updates guidance and announces refinancing including equity issue
- Ny publicering Faron Pharmaceuticals Redeye Faron Pharmaceuticals: First patient dosed in BLAZE trial
- Ny publicering Avensia Redeye Avensia: Cost savings in Commerce as mid-term market outlook remains soft
- Ny publicering Scanfil Carnegie/Penser uppdragsanalys Scanfil: Postcard from MB Elettronica site visit and updated targets
- Ny publicering Gentoo Media Carnegie/Penser uppdragsanalys Gentoo Media: Negative guidance revision and bond refinancing
- Ny publicering Calviks Carnegie/Penser uppdragsanalys Calviks: Big steps in Norway, contemplates new bonds – correction
- Ny publicering Calviks Carnegie/Penser uppdragsanalys Calviks: Big steps in Norway, contemplates new bonds
- Ny publicering Bactiguard Holding Carnegie/Penser uppdragsanalys Bactiguard: Further progress towards stability expected – Q3 preview
- Ny publicering Alzinova Carnegie/Penser uppdragsanalys Alzinova: Supportive early results for diagnostics programme
- Ny publicering SciBase Holding Analyst Group Kommentar på utfallet i SciBase företrädesemission
2026-09-30
30 händelser- Utfallstyp ändrad Viva Wine Group Carnegie/Penser uppdragsanalys prissatt ur kursserien → uppköpt mot kontant ersättning
- Bevakning avslutad Viva Wine Group Carnegie/Penser uppdragsanalys okänd bevakningsstatus → bevakning avslutad
- Utfallstyp ändrad Viva Wine Group Carlsquare Equity Research prissatt ur kursserien → uppköpt mot kontant ersättning
- Ny publicering Scandinavian Enviro Systems Redeye Enviro: Reconstruction moves closer to completion
- Ny publicering OncoZenge Redeye OncoZenge: Guarantor compensation and bridge loan set-off
- Ny publicering KD Ventures Redeye KDventures: Impressive but Dilutive Equity Issue for AnaCardio
- Ny publicering Vuxen Group Kalqyl Vuxen Group: Rapportkommentar Q1'26/27
- Ny publicering AIRA Kalqyl Aira: VD-intervju med Daniel Wikberg om Aira för Fortnox
- Ny publicering W5 Solutions Redeye W5 Solutions: Preliminary Q3-results softer than expected
- Ny publicering Smoltek Redeye Redeye initiates coverage of Smoltek
- Ny publicering Senzime Redeye Senzime: Business update with a clear message on financing
- Ny publicering Physitrack Redeye Physitrack: EMR launch marks shift from add-on to system of record
- Ny publicering InCoax Networks Redeye InCoax: Nokia exits partnership – major setback, but implications remain unclear
- Ny publicering Freemelt Redeye Freemelt: Another contract with F4E
- Ny publicering CombinedX Redeye CombinedX (Preview Q3): Solid order intake supports stronger H2
- Ny publicering Cinclus Pharma Redeye Cinclus Pharma: Last patient visit completed in pivotal HEEALING1 study
- Ny publicering Better Collective Redeye Better Collective: Comment on guidance update after Brazil online gambling ban
- Ny publicering Wyld Networks Dagens Börs TEKNISK ANALYS: Wyld Networks, ny köpsignal
- Ny publicering Wyld Networks Dagens Börs TEKNISK ANALYS: Wyld Network (+27,68 %)
- Ny publicering W5 Solutions Carnegie/Penser uppdragsanalys W5 Solutions: Strong sales growth, but profitability remains the challenge
- Ny publicering Paxman Carnegie/Penser uppdragsanalys Analyspodden - Avsnitt 383 - Tillväxtresan i USA & nya produktmöjligheter - VD-intervju med Paxman
- Ny publicering Micro Systemation Carnegie/Penser uppdragsanalys Micro Systemation: Oxygen’s troubles create potential opportunity for MSAB
- Ny publicering Kebni Carnegie/Penser uppdragsanalys Kebni: Divests ScaffSense
- Ny publicering Idun Industrier Carnegie/Penser uppdragsanalys Idun Industrier: Earnings growth accelerating after weaker Q2 – Q3 preview - correction
- Ny publicering Idun Industrier Carnegie/Penser uppdragsanalys Idun Industrier: Earnings growth accelerating after weaker Q2 – Q3 preview
- Ny publicering Carasent Carnegie/Penser uppdragsanalys Carasent: Margin expansion on course – Q3 preview
- Ny publicering Pila Pharma Carlsquare Equity Research Equity research Pila Pharma: XEN-D0501 returns to the clinic, with higher exposure now in focus
- Ny publicering Immunovia Carlsquare Equity Research Equity research, Immunovia: Announced rights issue and pause of coverage
- Ny publicering Pila Pharma Analyst Group Kommentar på att Pila Pharma har inlett rekryteringen till PP-CT04 inom obesitas
- Ny publicering Pila Pharma Analyst Group Comment on Pila Pharma’s Initiation of Recruitment for PP-CT04 in Obesity
2026-09-26
4 händelser- Ny publicering Alzinova Dagens Börs TEKNISK ANALYS: Alzinova – stor potenial
- Ny publicering Sensys Gatso Group Carnegie/Penser uppdragsanalys Sensys Gatso Group – interview with the CEO
- Ny publicering Aptahem Analyst Group Intervju med Aptahems VD Mikael Lindstam
- Ny publicering Aptahem Analyst Group Aptahem
2026-09-23
11 händelser- Ny publicering SSH Communications Security Redeye SSH: Another Mild Profit Warning
- Ny publicering OncoZenge Redeye OncoZenge: Rights issue concludes at ~92% subscription
- Ny publicering NextCell Pharma Redeye NextCell Pharma: Our thoughts ahead of the phase ll readout
- Ny publicering Neem’s Hill Redeye Neem’s Hill: Positive update ahead of Q3 report
- Ny publicering BioArctic Redeye BioArctic (Q2 and pipeline review): Iqlik in focus
- Ny publicering BiBBInstruments Redeye BiBBInstruments: New US orders from TaeWoong
- Ny publicering Divio Technologies Impala Nordic Divio Technologies – Bevakningskommentar
- Ny publicering White Pearl Technology Group Dagens Börs TEKNISK ANALYS: WPTG – AI orders för 295m
- Ny publicering Viva Wine Group Carnegie/Penser uppdragsanalys Viva Wine Group: Discontinuation of coverage
- Ny publicering Nosa Plugs Analyst Group Comment on Nosa Plugs’ Exclusive Distribution Agreement in Morocco
- Ny publicering Mahvie Minerals Analyst Group Kommentar på Mahvie Minerals avsiktsförklaring med Dragon Mining om anrikning av guldmalm från Haveri
2026-09-22
8 händelser- Ny publicering Neovici Analyst Group Neovici Q2-26
- Ny publicering Lumito Analyst Group Kommentar på Lumitos framgångsrika integration av SCIZYS i ett automatiserat laboratorieflöde hos CliniSciences
- Ny publicering Sdiptech Redeye Weekly Edge Case: Sdiptech
- Ny publicering Lytix Biopharma Redeye Lytix Biopharma: A Quick Route to Market Prioritised
- Ny publicering BONESUPPORT Redeye BONESUPPORT: Completes CERAMENT V FDA data submission
- Ny publicering Alligator Bioscience Redeye Alligator Bioscience: 17% Preliminary Subscription Rate
- Ny publicering Vivesto Carnegie/Penser uppdragsanalys Vivesto - Framsteg inom veterinärmedicin
- Ny publicering Calviks Carnegie/Penser uppdragsanalys Calviks: Subshore acquisition marks major Norway expansion
2026-09-20
78 händelser-
Nytt bolag 53 bolag Carlsquare Equity Research Zinzino, White Pearl Technology Group, Viva Wine Group, Thinc Collective, …
- Zinzino
- White Pearl Technology Group
- Viva Wine Group
- Thinc Collective
- Teneo AI
- Svenska Aerogel
- Spotlight Group
- SBB i Norden
- Risk Intelligence
- Prolight Diagnostics
- Pila Pharma
- Orion Corporation
- Omda
- Odinwell
- Observit
- Nosa Plugs
- Nodebis
- Nischer Properties
- Nexam Chemical
- NeoDynamics
- Monivent
- Modus Therapeutics
- Midsummer
- Medivir
- Medclair Invest
- Lokotech
- Lohilo Foods
- KlaraBo
- Kancera
- InCoax
- Immunovia
- Herantis Pharma
- H&D Wireless
- Hanza
- Hansa Biopharma
- Gubra
- GHP Specialty Care
- Frequentis
- Fable Media
- Enrad
- Elicera Therapeutics
- edyoutec
- CellaVision
- CDON
- Cantargia
- Candles Scandinavia
- Boozt
- Biovica International
- Biosergen
- Bentley Endovascular Group
- Arctic Minerals
- Angler Gaming
- Alzinova
- Utfallstyp ändrad OrderYOYO Analyst Group går inte att prissätta → uppköpt mot kontant ersättning
- Utfallstyp ändrad Huddlestone Analyst Group går inte att prissätta → avnoterat
- Utfallstyp ändrad Hoylu Analyst Group går inte att prissätta → avnoterat
- Utfallstyp ändrad Calliditas Therapeutics Redeye går inte att prissätta → uppköpt mot kontant ersättning
- Utfallstyp ändrad Rolling Optics Holding Carnegie/Penser uppdragsanalys går inte att prissätta → avnoterat
- Utfallstyp ändrad Calliditas Therapeutics Carnegie/Penser uppdragsanalys går inte att prissätta → uppköpt mot kontant ersättning
- Utfallstyp ändrad ArcAroma Carnegie/Penser uppdragsanalys går inte att prissätta → avnoterat
- Utfallstyp ändrad Hoylu Analysguiden går inte att prissätta → avnoterat
- Utfallstyp ändrad Newton Nordic Analyst Group går inte att prissätta → avnoterat
- Utfallstyp ändrad Josab Water Solutions Analyst Group går inte att prissätta → avnoterat
- Utfallstyp ändrad Newton Nordic Analyst Group avnoterat → går inte att prissätta
- Utfallstyp ändrad Josab Water Solutions Analyst Group avnoterat → går inte att prissätta
- Utfallstyp ändrad Disruptive Pharma Redeye prissatt ur kursserien → går inte att prissätta
- Utfallstyp ändrad Fingerprint Cards Carnegie/Penser uppdragsanalys går inte att prissätta → avnoterat
- Utfallstyp ändrad Disruptive Pharma Redeye går inte att prissätta → prissatt ur kursserien
- Utfallstyp ändrad ProstaLund Västra Hamnen Corporate Finance går inte att prissätta → avnoterat
- Utfallstyp ändrad Smart Wires Technology Redeye går inte att prissätta → avnoterat
- Utfallstyp ändrad Scandion Oncology Redeye går inte att prissätta → avnoterat
- Utfallstyp ändrad Lipigon Pharmaceuticals Redeye går inte att prissätta → avnoterat
- Utfallstyp ändrad Besqab Carnegie/Penser uppdragsanalys går inte att prissätta → prissatt ur kursserien
- Utfallstyp ändrad TopRight Nordic Mangold Insight går inte att prissätta → konkurs
- Utfallstyp ändrad Toleranzia Mangold Insight går inte att prissätta → avnoterat
- Bevakning avslutad TopRight Nordic Mangold Insight aktivt bevakad → bevakning avslutad
- Bevakning avslutad Qlosr Group B Mangold Insight aktivt bevakad → bevakning avslutad
- Bevakning avslutad Cyber Security 1 Mangold Insight aktivt bevakad → bevakning avslutad
2026-09-19
24 händelser- Nytt bolag Pila Pharma Analyst Group
- Nytt bolag Savelend Kalqyl
- Nytt bolag Hilbert Group Kalqyl
- Nytt bolag Briox Kalqyl
- Nytt bolag AIRA Kalqyl
- Nytt bolag Adverty Kalqyl
- Utfallstyp ändrad Skogsfond Baltikum Carnegie/Penser uppdragsanalys går inte att prissätta → avnoterat
- Utfallstyp ändrad Neem's Hill Carnegie/Penser uppdragsanalys går inte att prissätta → prissatt ur kursserien
- Utfallstyp ändrad Lipidor Carnegie/Penser uppdragsanalys går inte att prissätta → konkurs
- Utfallstyp ändrad Idogen Carnegie/Penser uppdragsanalys går inte att prissätta → konkurs
- Utfallstyp ändrad Everysport Group Carnegie/Penser uppdragsanalys går inte att prissätta → uppköpt mot kontant ersättning
- Bevakning avslutad Lipidor Carnegie/Penser uppdragsanalys okänd bevakningsstatus → bevakning avslutad
- Bevakning avslutad Idogen Carnegie/Penser uppdragsanalys okänd bevakningsstatus → bevakning avslutad
- Bevakning avslutad Wall To Wall Group Carnegie/Penser uppdragsanalys okänd bevakningsstatus → bevakning avslutad
-
Nytt bolag 10 bolag Carnegie/Penser uppdragsanalys Surgical Science Sweden, Scandinavian ChemoTech, Probi, Pierce Group, …
2026-09-18
154 händelser-
Nytt bolag 77 bolag Carnegie/Penser uppdragsanalys Tempest Security, Talkpool, Taaleri, STRAX, …
- Tempest Security
- Talkpool
- Taaleri
- STRAX
- SenzaGen
- ScandiDos
- SBB
- Ortoma
- Nanologica
- MAG Interactive
- Humble Group
- GiG Software
- Faron Pharmaceuticals
- Eastnine
- Devyser Diagnostics
- CodeMill
- Bonava
- Bio-Works Technologies
- BE Group
- Attana
- Zwipe
- Upsales Technology
- Tourn International
- Physitrack
- Paxman
- OncoZenge
- Niutech Group
- Modus Therapeutics
- Midsummer
- Medicover
- Lifecare
- Lagercrantz Group
- Instalco
- Infracom
- Gigasun
- Enzymatica
- Elicera Therapeutics
- Bergs Timber
- Beijer Alma
- Abliva
- XMReality
- SaveLend Group
- Norsk Titanium
- MedHelp Care
- ITAB Group
- Hansa Biopharma
- Gentoo Media
- Corline Biomedical
- Calviks
- Calliditas Therapeutics
- AAC Clyde Space
- Keo Capital
- Intervacc
- Initiator Pharma
- Waystream Group
- W5 Solutions
- Terranor Group
- Svedbergs Group
- Spago Nanomedical
- PowerCell Sweden
- Nordic LEVEL Group
- Net Insight
- Medivir
- Maven Wireless Sweden
- Iconovo
- HANZA
- Eolus Vind
- Ascelia Pharma
- Arise
- Arcoma
- Angler Gaming
- ALM Equity
- eEducation Albert
- Disruptive Pharma
- Ependion
- Ziccum
- Diamyd Medical
-
Bevakning avslutad 20 bolag Carnegie/Penser uppdragsanalys Modus Therapeutics, Gigasun, Norsk Titanium, Integrum, …
- Modus Therapeutics
- Gigasun
- Norsk Titanium
- Integrum
- Gapwaves
- VO2 Cap Holding
- Stockwik Förvaltning
- Sivers Semiconductors
- KDventures
- Beyond Frames Entertainment
- Maven Wireless Sweden
- Arcoma
- Angler Gaming
- Transtema Group
- Raketech
- OptiCept Technologies
- Disruptive Pharma
- Fingerprint Cards
- Checkin.com Group
- Diamyd Medical
-
Nytt bolag 42 bolag Mangold Insight Zoomability, Toleranzia, SensoDetect, Scandinavian Enviro Systems, …
- Zoomability
- Toleranzia
- SensoDetect
- Scandinavian Enviro Systems
- Northern CapSek Ventures
- Hedera Group
- Genetic Analysis
- Finepart
- Dicot
- Brilliant Future
- Auriant Mining
- Alzinova
- 2cureX
- XP Chemistries
- Wyld Networks
- Vimab Group
- Trianon B
- Transfer Group
- TopRight Nordic
- Tessin Nordic Holding
- S2Medical B
- Qlosr Group B
- Prolight Diagnostics
- PolarCool
- My Beat
- Miris Holding
- Mantex
- Lumito
- Katalysen Ventures
- JonDeTech Sensors
- Eurobattery Minerals
- Episurf Medical B
- Enersize
- Double Bond Pharmaceutical B
- Cyber Security 1
- Crustal Resources B
- Chargepanel
- Cardeon
- Bluelake Mineral
- BlincVision B
- Biosergen
- Aptahem
- Nytt bolag AddLife Redeye
- Ny publicering Oncopeptides Redeye Oncopeptides: CHMP Recommends Third-Line Treatment Extension
- Ny publicering NYORDA Redeye NYORDA: Full market launch of EMNA AI
- Ny publicering GomSpace Group Redeye GomSpace: Wins new European partner
- Ny publicering OncoZenge Impala Nordic OncoZenge and the Dental Opportunity
- Ny publicering ECOMB Impala Nordic ECOMB – Bolagsanalys
- Ny publicering Xoma Dagens Börs TEKNISK ANALYS: XOMA rusar efter Riktad
- Ny publicering Xoma Dagens Börs TEKNISK ANALYS: XOMA – ny köpsignal!
- Ny publicering Zenith Energy Analyst Group Comment on Zenith’s Rising Cash Generation from Its Italian Energy Operations
- Ny publicering Umida Group Analyst Group Kommentar på Umidas nya centrala listningar för Joluca
- Ny publicering Tellusgruppen Analyst Group Kommentar på Tellusgruppens förvärv av Sandvikens Friskola AB
- Ny publicering Synexo Group Analyst Group Kommentar på Synexos augustiuppdatering
- Ny publicering Lumito Analyst Group Kommentar på extern studie som visar nya tillämpningsområden för Lumitos SCIZYS inom immunologisk forskning
- Ny publicering Railcare Group Analysguiden Railcare Group: Överreaktion
- Ny publicering Railcare Group Analysguiden Railcare Group: Overreaction
2026-09-17
97 händelser-
Nytt bolag 95 bolag Redeye 2cureX, Smart Wires Technology, Sileon, PMD Device Solutions, …
- 2cureX
- Smart Wires Technology
- Sileon
- PMD Device Solutions
- Orphazyme
- Opsy Holding
- Netmore Group
- LIDDS
- Inzile
- Fuud
- CoinShares
- Calmark Sweden
- Berner Industrier
- Aspire Global
- TECO 2030
- Scandion Oncology
- Northbaze Group
- Lipum
- Lipigon Pharmaceuticals
- ISR Immune System Regulation
- Hoylu
- Guard Therapeutics
- Global Gaming 555
- Frontwalker
- ENLABS
- Dala Energi
- Cyxone
- Asarina Pharma
- AroCell
- Anoto Group
- Abliva
- ZetaDisplay
- Urb-it
- Nepa
- Mestro
- EmbeddedArt Group
- Coala Life
- Smoltek
- Prostatype Genomics
- Precise Biometrics
- Pila Pharma
- Lifecare
- KD Ventures
- Jumpgate
- Intervacc
- INQ Group
- FM Mattsson
- Evaxion Biotech
- Climeon
- Circio Holding
- CDON
- Careium
- Boreo
- Bio-Works Technologies
- BiBBInstruments
- Azelio
- aXichem
- Acuvi
- Vicore Pharma Holding
- Scandinavian Enviro Systems
- RLS Global
- Qlife Holding
- Nexstim
- Neodynamics
- Mycronic
- JonDeTech Sensors
- IDL Diagnostics
- Fractal Gaming Group
- Eolus
- Coegin Pharma
- Wyld Networks
- Westpay
- STRAX
- Serstech
- Safello Group
- Remedy Entertainment
- Relais Group
- Raketech
- PowerCell Sweden
- Pagero Group
- Orexo
- OEM International
- Freja eID Group
- Fram Skandinavien
- Flerie
- Ferroamp
- Fantasma Games
- Clavister
- ChromoGenics
- BrightBid Group
- BICO Group
- Bambuser
- Amniotics
- Advenica
- AAC Clyde Space
- Ny publicering Sleep Cycle Redeye Sleep Cycle: Reorganisation trims headcount, targets SEK35m in annual savings
- Ny publicering BONESUPPORT Redeye BONESUPPORT: SOLARIO published in NEJM
2026-09-16
57 händelser-
Nytt bolag 57 bolag Redeye Maximum Entertainment, Zelluna Immunotherapy, Xplora Technologies, Tessin Nordic Holding, …
- Maximum Entertainment
- Zelluna Immunotherapy
- Xplora Technologies
- Tessin Nordic Holding
- Stillfront Group
- Spago Nanomedical
- SOZAP
- SenzaGen
- Respiratorius
- QleanAir
- Polygiene Group
- Penneo
- Ortoma
- Nanexa
- Mentice
- Lime Technologies
- IRRAS
- Inhalation Sciences
- Iconovo
- Herantis Pharma
- Fragbite Group
- ES Group
- Enzymatica
- Elicera Therapeutics
- Dynavox Group
- Cheffelo
- Bioservo Technologies
- Alelion Energy Systems
- XMReality
- Thunderful Group
- Sensys Gatso Group
- Sedana Medical
- Seamless Distribution Systems
- Railcare Group
- Q-linea
- Proact IT Group
- OncoZenge
- Ngenic
- Newbury Pharmaceuticals
- Mendus
- LifeClean
- Lifco
- Klaria Pharma Holding
- Impact Coatings
- HANZA
- Gasporox
- FlexQube
- Fable Media Group
- Ependion
- Efecte
- Dignitana
- CTEK
- Binero Group
- BIMobject
- BeammWave
- Annexin Pharmaceuticals
- AcouSort